Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by POLK, B. F.
Right arrow Articles by DeGIROLAMI, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by POLK, B. F.
Right arrow Articles by DeGIROLAMI, P. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 115, No. 1: 19-25
Copyright © 1982 by The Johns Hopkins University School of Hygiene and Public Health

research-article

A CONTROLLED COMPARISON OF JOINT REACTIONS AMONG WOMEN RECEIVING ONE OF TWO RUBELLA VACCINES

B. FRANK POLK1,, JOHN F. MODLIN2, JULIE A WHITE3 and PAOLA C. DeGIROLAMI4

1Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School Boston, MA
2Department of Medicine, Children's Hospital Medical Center, and Harvard Medical School Boston, MA
3Epidemiology Unit, New England Deaconess Hospital, and Harvard Medical School Boston, MA
4Pathology Department, New England Deaconess Hospital, and Harvard Medical School Boston, MA

Reprint requests to Dr. Polk, Channing Laboratory, 180 Longwood Avenue, Boston, MA 02115

While transient rheumatic side-effects are not uncommon in women receiving any of the attenuated rubella virus vaccines yet developed, few comparative data are available on the only rubella vaccine currently available in the United States—the RA 27/3 vaccine. In this study, the frequency and severity of joint reactions were compared among seronegative women receiving HPV77DE5 vaccine (n = 59) or RA 27/3 vaccine (n = 53), and in seropositive vaccinees receiving either vaccine (n = 60). The proportions of vaccinees developing arthralgia/arthritis were similar (29 per cent and 26 per cent, respectively) in the seronegative groups, and were significantly higher than in the seropositive control group (3%). The onset of symptoms was earlier and their duration was briefer in those receiving RA 27/3 vaccine compared to the HPV77DE3 vaccine recipients. No chronic or recurrent symptoms were observed. These data, along with previous studies, suggest that while transient rheumatic reactions following rubella vaccination are not uncommon, they are not associated with serious disability and should not interfere with ongoing immunization programs.

arthritis; rubella vaccine; vaccines; attenuated


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.